Development of a recombinant antibody to target peptides and proteins to sialoadhesin-expressing macrophages

BMC Biotechnology

Karen Ooms²  Hanne Van Gorp²  Tim Van Gaever²  Hans J Nauwynck²  Peter L Delputte¹ 

[1] Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium

[2] Laboratory of Virology, Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, Merelbeke, 9820, Belgium

关键词: Cell-directed therapy;    Targeting;    Recombinant antibody;    Siglec-1;    CD169;    Sialoadhesin;    Macrophage;   

Others  :  1123181
DOI  :  10.1186/1472-6750-13-33

 received in 2012-11-20, accepted in 2013-04-04,  发布年份 2013

【 摘 要 】

Background

Sialoadhesin (Sn)-expressing monocytes/macrophages have been associated with several diseases like inflammatory and autoimmune disorders as well as viral infections, and they also appear to play a role in the initiation of an adaptive immune response. This makes Sn-expressing cells not only attractive targets for cell-directed therapies, but also an appealing target for vaccination. Furthermore, since Sn was shown to be an endocytic receptor, the conjugation of effector molecules to an Sn-specific ligand should allow intracellular delivery of these conjugates. Previously, we developed functional Sn-specific immunoconjugates that were generated via chemical coupling. Although successful, the system requires significant optimization for each immunoconjugate to be made. To generate a more flexible and controlled system, we developed a recombinant antibody vector allowing the creation of genetic antibody fusion constructs. This paper reports on the characterization of the recombinant antibody and the evaluation of its use for Sn-directed targeting.

Results

The variable domains of the porcine Sn-specific monoclonal antibody 41D3 were sequenced and cloned in frame with a mouse IgG1 backbone. Transfection of HEK293T cells with the resulting plasmid led to the secretion of fully assembled IgG into the culture medium. This recombinant antibody rec41D3 was shown to specifically bind to porcine Sn with a comparable affinity as the native monoclonal antibody. In addition, rec41D3 also induced Sn endocytosis in primary macrophages and resided for prolonged times in early/late endosomes. To allow the generation of antibody fusion constructs, a multiple cloning site was introduced at the C-terminus of the heavy chain. Two fusion constructs were generated, one containing a V5 peptide tag and one containing an eGFP molecule. Both constructs were shown to be efficiently produced in HEK293T cells and easily purified using standard protein G chromatography. In addition, both V5 and eGFP were shown to be co-internalized together with rec41D3 into Sn-expressing primary macrophages.

Conclusions

A recombinant antibody allowing targeted delivery of peptides and proteins to Sn-expressing macrophages was developed. Production and purification of antibody fusion constructs was possible without major optimization and with batch to batch consistency, confirming the development of a versatile antibody vector to evaluate Sn-directed targeting strategies in a porcine animal model.

【 授权许可】

   
2013 Ooms et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Martinez-Pomares L, Gordon S: CD169+ macrophages at the crossroads of antigen presentation. Trends Immunol 2012, 33(2):66-70.
• [2]Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, Fink K, Henrickson SE, Shayakhmetov DM, Di Paolo NC: Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 2007, 450(7166):110-114.
• [3]Carrasco YR, Batista FD: B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity 2007, 27(1):160-171.
• [4]Phan TG, Grigorova I, Okada T, Cyster JG: Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 2007, 8(9):992-1000.
• [5]Phan TG, Green JA, Gray EE, Xu Y, Cyster JG: Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 2009, 10(7):786-793.
• [6]Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerundolo V, Batista FD: CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 2010, 11(4):303-312.
• [7]Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M: CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011, 34(1):85-95.
• [8]Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O’Toole T, Kraal G, Limmer A: Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc Natl Acad Sci USA 2010, 107(1):216-221.
• [9]Revilla C, Poderoso T, Martinez P, Alvarez B, Lopez-Fuertes L, Alonso F, Ezquerra A, Dominguez J: Targeting to porcine sialoadhesin receptor improves antigen presentation to T cells. Vet Res 2009, 40(3):14.
• [10]Delputte PL, Van Gorp H, Favoreel HW, Hoebeke I, Delrue I, Dewerchin H, Verdonck F, Verhasselt B, Cox E, Nauwynck HJ: Porcine sialoadhesin (CD169/Siglec-1) is an endocytic receptor that allows targeted delivery of toxins and antigens to macrophages. PLoS One 2011, 6(2):e16827.
• [11]Poderoso T, Martinez P, Alvarez B, Handler A, Moreno S, Alonso F, Ezquerra A, Dominguez J, Revilla C: Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs. Vaccine 2011, 29(29–30):4813-4820.
• [12]Kratzer R, Mauvais FX, Burgevin A, Barilleau E, van Endert P: Fusion proteins for versatile antigen targeting to cell surface receptors reveal differential capacity to prime immune responses. J Immunol 2010, 184(12):6855-6864.
• [13]Chen WC, Kawasaki N, Nycholat CM, Han S, Pilotte J, Crocker PR, Paulson JC: Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169. PLoS One 2012, 7(6):e39039.
• [14]Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR: Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood 2001, 97(1):288-296.
• [15]Crocker PR, Paulson JC, Varki A: Siglecs and their roles in the immune system. Nat Rev Immunol 2007, 7(4):255-266.
• [16]Wu C, Rauch U, Korpos E, Song J, Loser K, Crocker PR, Sorokin LM: Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J Immunol 2009, 182(10):6508-6516.
• [17]Xiong YS, Zhou YH, Rong GH, Wu WL, Liang Y, Yang ZX, Geng HL, Zhong RQ: Siglec-1 on monocytes is a potential risk marker for monitoring disease severity in coronary artery disease. Clin Biochem 2009, 42(10–11):1057-1063.
• [18]Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J, Crocker PR: Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 1999, 98(2):213-219.
• [19]Huang Z, Zhang Z, Zha Y, Liu J, Jiang Y, Yang Y, Shao J, Sun X, Cai X, Yin Y: The effect of targeted delivery of anti-TNF-alpha oligonucleotide into CD169(+) macrophages on disease progression in lupus-prone MRL/lpr mice. Biomaterials 2012, 33(30):7605-7612.
• [20]Nycholat CM, Rademacher C, Kawasaki N, Paulson JC: In silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages. J Am Chem Soc 2012, 134(38):15696-15699.
• [21]Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K: Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci USA 2012, 109(40):16101-16106.
• [22]Delputte PL, Van Breedam W, Delrue I, Oetke C, Crocker PR, Nauwynck HJ: Porcine arterivirus attachment to the macrophage-specific receptor sialoadhesin is dependent on the sialic acid-binding activity of the N-terminal immunoglobulin domain of sialoadhesin. J Virol 2007, 81(17):9546-9550.
• [23]Nauwynck HJ, Pensaert MB: Effect of specific antibodies on the cell-associated spread of pseudorabies virus in monolayers of different cell types. Arch Virol 1995, 140(6):1137-1146.
• [24]Van Breedam W, Van Gorp H, Zhang JQ, Crocker PR, Delputte PL, Nauwynck HJ: The M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner. PLoS Pathog 2010, 6(1):e1000730.
• [25]Loughran ST, Loughran NB, Ryan BJ, D’Souza BN, Walls D: Modified His-tag fusion vector for enhanced protein purification by immobilized metal affinity chromatography. Anal Biochem 2006, 355(1):148-150.
• [26]Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N: The next generation of antibody-drug conjugates comes of age. Discov Med 2010, 10(53):329-339.
• [27]O’Reilly MK, Paulson JC: Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci 2009, 30(5):240-248.
• [28]Jandus C, Simon HU, von Gunten S: Targeting siglecs–a novel pharmacological strategy for immuno- and glycotherapy. Biochem Pharmacol 2011, 82(4):323-332.
• [29]Izquierdo-Useros N, Lorizate M, Puertas MC, Rodriguez-Plata MT, Zangger N, Erikson E, Pino M, Erkizia I, Glass B, Clotet B: Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol 2012, 10(12):e1001448.
• [30]Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W: Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005, 14(9):2436-2446.
• [31]Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF: Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10(20):7063-7070.
• [32]Stocker M, Tur MK, Sasse S, Krussmann A, Barth S, Engert A: Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 2003, 28(2):211-219.
• [33]Hu CC, Ji HM, Chen SL, Zhang HW, Wang BQ, Zhou LY, Zhang ZP, Sun XL, Chen ZZ, Cai YQ: Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int J Cancer 2010, 127(9):2222-2229.
• [34]Krauss J, Exner E, Mavratzas A, Seeber S, Arndt MA: High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cells. Methods Mol Biol 2009, 525:471-490. xiv
• [35]Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS: Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26(8):925-932.
• [36]Wensvoort G, Terpstra C, Pol JM, ter Laak EA, Bloemraad M, de Kluyver EP, Kragten C, van Buiten L, den Besten A, Wagenaar F: Mystery swine disease in The Netherlands: the isolation of Lelystad virus. Vet Q 1991, 13(3):121-130.
• [37]Vanderheijden N, Delputte PL, Favoreel HW, Vandekerckhove J, Van Damme J, van Woensel PA, Nauwynck HJ: Involvement of sialoadhesin in entry of porcine reproductive and respiratory syndrome virus into porcine alveolar macrophages. J Virol 2003, 77(15):8207-8215.
• [38]Duan X, Nauwynck HJ, Favoreel HW, Pensaert MB: Identification of a putative receptor for porcine reproductive and respiratory syndrome virus on porcine alveolar macrophages. J Virol 1998, 72(5):4520-4523.
• [39]Zinchuk V, Zinchuk O: Quantitative colocalization analysis of confocal fluorescence microscopy images. Curr Protoc Cell Biol 2008, Chapter 4:Unit 4-Unit 19.